Day One Biopharmaceuticals, Inc vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
4.5
Bearish
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
DAWN
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ currently unprofitable (-68% margin).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
HOLD
Target $21.50 (-0.1%)
6 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
DAWN
JNJ
—
Trailing P/E
26.3×
-112.4×
Forward P/E
17.9×
-67.8%
Profit Margin
21.8%
89.1%
Gross Margin
68.0%
-22.7%
ROE
26.4%
83.9%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
-1.75
Beta
0.33
—
Price / Book
—
$2.2B
Market Cap
$546.9B
$6 – $22
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →